Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04319237 · ClinicalTrials.gov registry record
Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes
A clinical trial, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- 60
- Enrollment target
NCT04319237 is a clinical trial that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 60 participants.
The verdict
NCT04319237 has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
The purpose of the study is to assess self-reported side effects and neurocognitive (brain, mood and thinking) functioning among patients treated with commercial axi-cel therapy.
Interventions
- OTHER Handgrip strength test
- BEHAVIORAL Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR)
- BEHAVIORAL Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS)
- BEHAVIORAL Neuropsychological Assessment - Color Trails
- BEHAVIORAL Neuropsychological Assessment -Stroop Color and Word Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-03-10 |
| Est. Completion | 2023-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04319237
The ClinicalTrials.gov registry entry for NCT04319237 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Handgrip strength test is the first listed.
NCT04319237 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04319237 about?
NCT04319237 is a clinical study titled "Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes". The purpose of the study is to assess self-reported side effects and neurocognitive (brain, mood and thinking) functioning among patients treated with commercial axi-cel therapy.
What is the current status of trial NCT04319237?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2020-03-10. Estimated completion is 2023-07-31.
What interventions are being tested in trial NCT04319237?
The interventions under investigation include: Handgrip strength test (OTHER), Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR) (BEHAVIORAL), Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS) (BEHAVIORAL), Neuropsychological Assessment - Color Trails (BEHAVIORAL), Neuropsychological Assessment -Stroop Color and Word Test (BEHAVIORAL).
Who is sponsoring clinical trial NCT04319237?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.